Did COVID-19 Truly Shift Anticoagulation Practice? Insights from Google Trends

View at publisher Summarise with VIRAT
Authors: Giuseppe Lippi, Camilla Mattiuzzi
Cited by: 0
References: 3

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We read with interest the recent article by Fan et al, who explored whether the coronavirus disease 2019 (COVID-19) pandemic materially influenced anticoagulant prescribing patterns across different health care systems.[ 1 ] Their comparative overview provides an important contribution to understanding how structural characteristics, national policies, and clinical infrastructure shaped therapeutic decision-making during such an unprecedented global disruption. To complement their observations from a different methodological perspective, we explored infodemiological patterns using Google Trends, analyzing relative search volumes between January 1, 2018, and January 1, 2026, for warfarin and the direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, dabigatran, and edoxaban—in the United States, the United Kingdom, and Australia. While online search behavior cannot be directly equated with prescription volumes, a recent systematic scoping review demonstrated that Google Trends data show a meaningful correlation with real-world medication utilization across several therapeutic areas, supporting its use as a surrogate indicator of public and professional attention.[ 2 ] The results of our analysis are shown in [ Fig. 1 ]. Across all three countries, apixaban consistently emerged as the most frequently searched anticoagulant throughout the observation period. This dominance was already evident prior to 2020 and persisted thereafter, suggesting that its prominence is structural rather than pandemic-induced. In the United States, a modest increase in search activity was observed around early 2020 for apixaban and warfarin, with a smaller rise for rivaroxaban. However, this pattern was transient. Following this short-lived amplification at the onset of the pandemic, search volumes stabilized, and only apixaban continued to display a gradual upward trajectory. The relative ranking of anticoagulants remained unchanged during the entire period, indicating that COVID-19 did not produce a substantial reordering of therapeutic attention in this setting. This observation aligns closely with the interpretation by Fan et al,[ 1 ] namely that the pandemic may have modestly reinforced existing trends in the United States rather than triggering a fundamental shift. Fig. 1 Relative Google search volume for oral anticoagulants in the United States, the United Kingdom, and Australia (2018–2026). The United Kingdom displayed a somewhat more dynamic pattern, yet still one that reflects acceleration rather than disruption. Apixaban searches rose steadily from 2020 onward, consistent with national guidance encouraging transition from warfarin to DOACs during the first lockdown phase. Warfarin-related searches showed a mild decline in the early pandemic period, but this decrease was neither profound nor sustained. Interestingly, toward the end of 2025, warfarin searches demonstrated a slight resurgence. This late increase may reflect renewed clinical attention to patient groups in whom DOACs are contraindicated or less suitable, such as those with mechanical heart valves, advanced renal impairment, or antiphospholipid syndrome. It may also signal re-engagement with anticoagulation services following normalization of health care operations, or heightened discussion of cost and reimbursement considerations within publicly funded systems. Importantly, despite the well-documented National Health System (NHS)-driven switching campaign, search interest in warfarin did not collapse, reinforcing the notion that its clinical role, although reduced, remains firmly embedded. In Australia, the curves were strikingly stable. Apixaban exhibited a gradual, uninterrupted increase throughout the entire search period, without any visible inflection points corresponding to pandemic waves. Warfarin and rivaroxaban followed largely flat or modestly declining trajectories, while dabigatran and edoxaban remained comparatively marginal. No discernible COVID-19-related discontinuity could be appreciated. These findings are fully consistent with the prescription-based analyses discussed by Fan et al,[ 1 ] suggesting that the Australian anticoagulation landscape evolved along its established path despite substantial societal disruption. When considered collectively, these infodemiological trends reinforce the broader conclusion that COVID-19 behaved more as an amplifier of pre-existing tendencies than as a transformative force. The transient peaks observed around 2020 likely reflect heightened awareness of thrombosis amid COVID-associated coagulopathy,[ 3 ] intense media coverage, and clinical uncertainty during the early pandemic phase. Nevertheless, these fluctuations were not followed by durable structural changes in relative attention among anticoagulants. The persistent dominance of apixaban across all examined regions appears to represent the maturation of long-term prescribing preferences rather than an acute pandemic effect. It is also noteworthy that warfarin maintained substantial search visibility across all countries analyzed. Despite repeated predictions of its progressive marginalization, the data suggest enduring relevance, likely reflecting its indispensable role in specific clinical scenarios and in a subset of the population where cost or indication constraints remain decisive. The relative stability in drug ranking further suggests therapeutic inertia and institutional continuity, even under crisis conditions. We are obviously aware that our approach has some limitations. Google Trends provides only visual and normalized relative search volumes rather than absolute prescription data and cannot differentiate between searches performed by clinicians, patients, researchers, or media outlets. Moreover, it cannot capture distinctions such as switching within stable therapeutic classes. Nevertheless, as a reflection of collective informational behavior, it offers a complementary perspective that converges meaningfully with prescription-based analyses. In summary, our findings support and extend the conclusions of Fan et al.[ 1 ] The COVID-19 pandemic did not uniformly reshape anticoagulation practice but selectively accelerated trajectories that were already underway. In systems where policy frameworks and digital infrastructure enabled rapid adaptation, a temporary intensification of DOAC-centered management was observed. In others, established trends continued largely uninterrupted. The experience underscores that therapeutic evolution in anticoagulation is driven primarily by structural, economic, and clinical determinants, with global crises acting chiefly as stress tests rather than catalysts of wholesale transformation. Publication History Received: 18 February 2026 Accepted: 17 March 2026 Article published online: 27 March 2026 © 2026. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Data-Driven Disease Surveillance COVID-19 and healthcare impacts

Publication details

Journal / source
Seminars in Thrombosis and Hemostasis
Publication date
27 March 2026
Language
EN